Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 14, 2008

RXi Gains Rights to Oral Delivery Technology for RNAi Drugs from Univ. of Massachusetts

  • RXi Pharmaceuticals licensed exclusive, worldwide rights from the University of Massachusetts Medical School (UMMS) to certain technology for the oral delivery of RNAi therapeutics. The technology, which targest macrophages, was developed by Michael Czech, Ph.D., professor and chair, program in molecular medicine at UMMS and an RXi founder, and Gary R. Ostroff, Ph.D., professor of molecular medicine at UMMS and an RXi collaborator.
  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.